Navigation Links
Savient Pharmaceuticals to Present Multiple Abstracts at The European League Against Rheumatism (EULAR) 2011 Annual Congress
Date:4/28/2011

EAST BRUNSWICK, N.J., April 28, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that three abstracts will be presented at the European League Against Rheumatism (EULAR) 2011 Annual Congress.  The conference will take place on May 25 - 28 in London, United Kingdom, and will feature the abstracts as two oral presentations and one poster presentation.

The first scheduled oral presentation and the poster session will address the prevalence of gout in Europe and current treatment practices and disease burdens for European gout patients using existing therapies. The second oral presentation will focus on long-term safety of KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy.  The presentation details are as follows:

  • Chronic Gout in Europe in 2010: Clinical Profile of 1,380 Patients in the U.K., Germany, France, Italy and Spain (Abstract # OP0112). This abstract will be presented in an oral presentation on Thursday, May 26, 2011 at 11:10 AM.
  • Safety and Efficacy of Long-Term Pegloticase (KRYSTEXXA®) Treatment in Adult Patients with Chronic Gout Refractory to Conventional Therapy (Abstract # OP0113). This data will be presented in an oral presentation on Thursday, May 26, 2011 at 11:20 AM.
  • Quality of Life, Work Impairment and Resource Utilisation Associated with Gout and Its Co-Morbidities Across Five EU Countries: Results from the European National Health and Wellness Survey (NHWS) (Abstract # FRI0275-HP). This data will be presented during the EULAR poster session on Friday, May 27, 2011 at 11:45 AM.

Additional details on these abstracts are available on the EULAR website at http://www.eular.org/.  

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.

SVNT - G


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
2. Savient Pharmaceuticals to Hold First Quarter 2011 Financial Results
3. Savient Pharmaceuticals to Present at the ROTH 23rd Annual OC Growth Stock Conference
4. Savient Pharmaceuticals to Present at the 31st Annual Cowen & Co. Health Care Conference
5. Savient Pharmaceuticals Announces U.S. Launch of KRYSTEXXA™; Reports Fourth Quarter and Year-End 2010 Financial Results
6. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2010 Results Conference Call on Friday, February 25, 2011
7. Savient Closes Sale of $230 Million in Convertible Senior Notes
8. Savient Announces Proposed Offering of $125 Million in Convertible Senior Notes
9. Savient Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
10. Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer
11. Savient Pharmaceuticals Announces Search for CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
Breaking Medicine News(10 mins):